Close

VarmX, a Dutch, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis, announced the publication in Nature Communications of a ground breaking LUMC study(1) on modified human factor X as a safe and effective reversal agent for prevention and treatment of bleeding in patients taking factor Xa oral anticoagulants.

More Articles ...

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok